276 related articles for article (PubMed ID: 37629304)
1. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
[No Abstract] [Full Text] [Related]
2. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
4. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
5. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma.
Park J; Chung C
Brain Tumor Res Treat; 2023 Apr; 11(2):86-93. PubMed ID: 37151150
[TBL] [Abstract][Full Text] [Related]
7. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
8. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
10. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.
Yoon HI; Wee CW; Kim YZ; Seo Y; Im JH; Dho YS; Kim KH; Hong JB; Park JS; Choi SH; Kim MS; Moon J; Hwang K; Park JE; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Sung KS; Song JH; Lee MH; Han MH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2021 Apr; 9(1):1-8. PubMed ID: 33913265
[TBL] [Abstract][Full Text] [Related]
11. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
[TBL] [Abstract][Full Text] [Related]
12. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
[TBL] [Abstract][Full Text] [Related]
13. Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.
Parekh K; LeBlang S; Nazarian J; Mueller S; Zacharoulis S; Hynynen K; Powlovich L
Neoplasia; 2023 Mar; 37():100876. PubMed ID: 36709715
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
15. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
16. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
18. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
Vitanza NA; Monje M
Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
[TBL] [Abstract][Full Text] [Related]
19. H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics.
Rechberger JS; Power BT; Power EA; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023 Jan; 27(1):9-17. PubMed ID: 36744399
[TBL] [Abstract][Full Text] [Related]
20. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
